

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1430-256

C# M#

BONNEFOY et al.

Group Art Unit: 1644

Serial No. (09/674,716

Examiner: P.N. Huynh

Filed: November 6, 2000

Date: October 6, 2003

Title: ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THEIR THERAPEUTIC  
USES

RECEIVED

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

OCT 16 2003

TECH CENTER 1600/2900

Sir:

**AMENDMENT UNDER 37 CFR § 1.111**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 17 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 7 minus highest number  
previously paid for 8 (at least 3) = 0 x \$ 86.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$290.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months) \$ 420.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00) \$ 0.00

☐ Please enter the previously unentered, filed☐ Submission attached**Subtotal \$ 420.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00


**TOTAL FEE ENCLOSED \$ 420.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
GRT:ap

NIXON &amp; VANDERHYTE P.C.

By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of  
BONNEFOY et al.

Appln. No. 09/674,716

Filed: January 22, 2001

FOR: ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THERAPEUTIC USES



Confirmation No.: 3589

Atty. Ref.: 1430-256

Group Art Unit: 1644

Examiner: P.N. Huynh

AMENDMENT UNDER 37 CFR § 1.111

RECEIVED

October 6, 2003

OCT 16 2003

U.S. Patent and Trademark Office  
**MS Non-Fee Amendment**  
Arlington, VA 22202

TECH CENTER 1600/2900

Sir:

In response to the pending Office Action (Paper No. 20) mailed May 6, 2003, entry and consideration of the following amendments and remarks are respectfully requested.

Amended portions of the **specification** are presented on page 2.

Paragraphs of the Description are amended.

The **claims** are presented on pages 3-5.

Claims 2, 4-9 and 12 are amended.

Claims 11 and 13-14 are canceled without prejudice or disclaimer.

Claim 20 is added.

**Remarks** begin on page 6.

10/10/2003 MAHMED1 00000042 09674716

01 FC:1252

420.00 OP